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Abstract: Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder that originates 
from antigen-experienced B lymphocytes that do not die and hence accumulate due to external 
survival signals or undergo apoptosis and are replenished by proliferating precursors. These 
neoplastic lymphocytes exhibit a characteristic immunophenotype of CD5+/CD19+/CD20+/
HLA-DR+/CD23+/sIgdim. Thus, the CD20 antigen has been an appealing target for therapy. 
The introduction of the monoclonal antibody rituximab (anti-CD20) enabled an outstanding 
advance in CLL treatment. The introduction of this monoclonal antibody into chemotherapy 
regimens has dramatically improved complete response rates and progression-free survival in 
patients with both untreated and relapsed CLL. Although only preliminary data from phase III 
confirmatory trials have been reported, the FCR regimen, which combines fludarabine and 
cyclophosphamide with rituximab, is currently the most effective treatment regimen for CLL 
patients, and has also been demonstrated to significantly improve overall survival . The success 
of rituximab and the identification of other CLL lymphocyte surface antigens have spurred the 
development of a multitude of monoclonal antibodies targeting distinct proteins and epitopes 
in an attempt to target CLL cells more effectively.
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Introduction
Chronic lymphocytic leukemia (CLL) represents the most frequent form of leukemia in 
the Western Hemisphere. The worldwide incidence of CLL ranges between 0 and 5.5 
cases per 100,000 people per year.1 The median age at presentation is approximately 
72 years, but 20% of patients present the disease before the age of 55 years.2,3 Although 
the overall median survival is approximately 10 years, the clinical course and prognosis 
of CLL are extremely heterogeneous: some patients never require treatment and have 
a survival similar to that of healthy age-matched individuals, whereas others have a 
poor prognosis and an early treatment requirement. Until the early 1980s, chloram-
bucil, which enabled only palliative therapy of the disease, represented the primary 
treatment for CLL. Subsequently, fludarabine, a purine analog, was introduced into 
the array of therapies for CLL. This drug showed a better debulking activity and an 
advantage in terms of progression-free survival (PFS) compared with chlorambucil.4–8 
With the aim of increasing its efficacy, fludarabine has been subsequently associ-
ated with other chemotherapeutic agents. Over the past decade the therapy for CLL 
has changed significantly with the introduction of monoclonal antibodies as well as 
rituximab (a chimeric anti-CD20 antibody) and alemtuzumab (a humanized anti-CD52 
antibody). Rituximab, initially administered as a single agent in relapsed/refractory 72
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CLL patients, showed a limited activity.9–12 Although 
phase II studies demonstrated that the addition of rituximab 
to fludarabine-based chemotherapy improved complete 
response (CR) rates and PFS in both previously untreated 
and relapsed patients.13–27 This review focuses specifically 
on the development and current applications of rituximab 
in the treatment of CLL.
Mechanism of action
CD20 antigen is a calcium channel that interacts with the B-cell 
immunoglobulin receptor complex.28 CD20 is expressed on 
90% of B-cell non-Hodgkin’s lymphomas (NHL),29,30 but 
occurs at lower density on CLL lymphocytes.31,32 Rituximab, 
a genetically engineered mouse/human chimeric IgG1-κ 
monoclonal antibody,33 is able to kill both neoplastic and 
normal B-cells expressing CD20 through indirect and direct 
cytotoxic mechanisms.34,35 Indirect mechanisms are comple-
ment-dependent cytotoxicity (CDC) and antibody-dependent 
cell-mediated cytotoxicity (ADCC). Direct mechanisms, 
although less defined, have also been reported and include 
growth inhibition, induction of apoptosis and chemosensi-
tization.34,35 CDC determines tumor cell lysis and increases 
phagocytosis deriving from activation of the complement 
cascade by the Fc portion of antibody bound to the neoplas-
tic lymphocytes.34,35 The engagement of effector cells with 
active Fc receptors determines antibody-coated tumor cell 
death resulting in ADCC.34,35 The relative importance of the 
ADDC has been demonstrated by Cartron et al, who showed 
an association between polymorphism of the IgG Fc receptor 
Fcgamma RIIIa gene and response to rituximab.36 Nonethe-
less, this association seems to be lost when rituximab is used in 
  combination with or after chemotherapy.37 Moreover it seems 
that the mechanisms of action of the rituximab depend on the 
tumor site.35 For example, ADCC and CDC are implicated in 
the killing of neoplastic cells circulating in the blood, while 
these mechanisms are probably less important for lymph node 
or extranodal sites.35 Furthermore CD55, CD59, CD20 and 
the complement seem to play important roles in rituximab-
induced cytotoxicity by a caspase-independent process pro-
ducing reactive oxygen species.34,35 Finally, rituximab induces 
apoptosis through activation of caspase-3 and sensitizes cells 
to proapoptotic stimuli.34,35
In vitro data show that rituximab sensitises neoplastic 
cells to the effects of chemotherapeutic drugs, thus support-
ing the use of combination chemotherapy with rituximab.34 
For example it seems that in vitro rituximab downregulates 
interleukin (IL)-10 and bcl-2 expression, making neoplastic 
B cells potentially more susceptible to fludarabine-induced 
apoptosis.38 Although there is a large variability of responses, 
rituximab resistance is a rare event. Experimental and clinical 
data support the role of tumor burden and rituximab exposure 
in the variability of the responses observed, McLaughlin et al 
showed that serum rituximab levels were sustained longer 
in patients with lower tumor burden and after the fourth 
infusion rather than after the first.39 These data have been 
confirmed by Daydé et al who reported that in mice rituximab 
concentrations were inversely correlated with tumor burden, 
and using a pharmacokinetic–pharmacodynamic model, they 
demonstrated that tumor burden significantly influenced 
rituximab efficacy.40 Moreover, O’Brien et al showed that 
rituximab was more efficacious at higher doses in CLL 
patients. Finally, other authors have demonstrated that it is 
possible to enhance rituximab efficacy through upregula-
tion of CD20 antigen expression on tumor cells from CLL 
patients by cytokines such as IL-4, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and tumour necrosis 
factor-α (TNF-α)34 More recently, resistance to rituximab 
was dramatically overcome enhancing complement activity, 
which has been demonstrated to be depressed in roughly 
half CLL patients41 by concurrent administration of fresh 
frozen plasma.42
Single-agent rituximab therapy
In phase I studies rituximab was administered at vari-
ous doses (single dose ranging from 10 to 500 mg/m2 or 
4 doses ranging from 125 to 375 mg/m2 weekly) in relapsed 
indolent NHL patients.43,44 Although both optimal dose 
and dose-limiting toxicity of rituximab have not been 
identified, the dose of 375 mg/m2 weekly for 4 weeks has 
been empirically chosen for subsequent studies.39,45,46 This 
schedule has been approved by the United States Food and 
Drug Administration (FDA) for the treatment of low grade 
NHL. In a pivotal phase II study, 50% of patients affected 
by follicular lymphoma achieved at least a partial remission 
(PR), while poor results were observed in relapsed/refractory 
small lymphocytic lymphoma (SLL) or CLL cases: overall 
response rate (ORR) 13% (4/30 patients).47 Similar modest 
results have been reported in other small trials in which ritux-
imab was administered as single-drug to treat relapsed CLL 
patients.9,47–51 Although a high discrepancy in terms of ORR 
(range 0%–90%) has been observed in these trials (Table 1), 
possibly due to the small number of enrolled cases and the 
higher number of rituximab doses administered in the study 
reported by Thomas et al (ORR: 90%), a short PFS has been 
noted in all studies.9,47–51 Since it has been assumed that the 
poor results achieved with single-agent rituximab were due 73
Rituximab in CLL
Cancer Management and Research 2010:2 73
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
to low CD20 expression on the surface of neoplastic CLL 
lymphocytes, in subsequent studies the efficacy of both higher 
number of cycles and higher dose of rituximab have been 
verified. Forty-four untreated CLL/SLL patients with at least 
one indication for therapy received 375 mg/m2 of rituximab 
weekly for 4 weeks and additional 4-week courses every 
6 months for up to 4 cycles only for patients with objective 
response or stable disease.10 The ORR after the first course of 
rituximab was 51% (4% CR). Twenty-eight patients received 
one or more additional courses of rituximab. The ORR was 
58% (CR 9%) and the 2-year PFS was 49%.10 Subsequently 
Thomas et al tested the activity of 8 courses of rituximab 
at standard dosage of 375 mg/m2 weekly in 31 early stage 
(Rai 0–II) CLL patients with high beta 2-microglobulin 
and without indication for therapy. Approximately 90% of 
patients achieved at least a PR and 19% a CR.52 In an attempt 
to improve ORR, two dose-escalation studies have been con-
ducted. The M.D. Anderson Cancer Center (MDACC) group 
escalated the rituximab dose from 350 mg/m2 to 2250 mg/m2 
in 40 previously treated CLL cases and in 10 other B-cell 
leukemias (n = 10).11 The ORR was 40% (in CLL 36%, all 
PR) and response was correlated with dose: 22% for patients 
treated from 500 to 825 mg/m2 vs 75% for those treated at 
the highest dose of 2250 mg/m2 (P = 0.007).54 Instead Byrd 
et al reported data relative to the efficacy of a schedule of 
rituximab given at 375 mg/m2 3 times per week for 4 weeks.12 
In 33 patients enrolled with previously treated SLL/CLL the 
ORR was 45%. Nevertheless, patients with del(17p) failed 
to achieve a single response.53 In all these studies rituximab 
showed a good activity in reducing peripheral blood disease, 
while in bulky nodal disease it was less effective.9–12,50–52 
Moreover, when given at high doses rituximab is more effi-
cacious, because as a single-agent it does not seem to affect 
the prognosis of CLL patients.
Rituximab in combination  
with chemotherapy
In the light of the results of several randomized studies in 
B-cell NHL patients in which rituximab in combination with 
different chemotherapy drugs achieved an improvement in 
terms of ORR and overall survival (OS), this monoclonal 
antibody was also used in combination with chemotherapy 
Table 1 Phase II trials of single-agent rituximab in chronic lymphocytic leukemia patients
Authors No of evaluable  
patients
Prior therapy Rituximab  
dose (mg/m2)
No of doses Overall response 
rate (%)
McLaughlin et al47 30 Yes 375 q 4 weeks 4 13
Nguyen et al48 10 Yes 375 q 4 weeks 4 10
Winkler et al49 9 Yes 375 q 4 weeks 4 11
Ladetto et al50 7 Yes 375 q 4 weeks 4 0
Huhn et al9 28 Yes 375 q 4 weeks 4 25
Thomas et al52 21 No 375 q 4 weeks 8 90
Itala et al51 24 Yes 375 q 4 weeks 4 35
Hainsworth et al10 44 No 375 q 4 weeks 4 51
Table 2 Phase II rituximab-based chemoimmunotherapy regimens in chronic lymphocytic leukemia patients
Authors No of  
evaluable 
patients










Byrd et al13 51 No Flu 375 q 4 weeks 6 90 47
Schulz et al18 31 No Flu 375 q 4 weeks 4 87 32
Wierda et al16 177 Yes Flu+Cy 500 q 4 weeks 6 73 25
Keating et al15 300 No Flu+Cy 500 q 4 weeks 6 94 72
Kay et al26 64 No Pent+Cy 375 q 4 weeks 6 91 41
Bosch et al23 68 No Flu+Cy+Mito 500 q 4 weeks 6 93 82
Faderl et al24 30 No Flu+Cy+Mito 500 q 4 weeks 6 96 83
Abbreviations: CR, complete response; Flu, fludarabine; Cy, cyclophosphamide; Pent, pentostatin; Mito, mitoxantrone.74
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agents in CLL cases (Table 2). In the 9712 study the 
  Cancer and Leukemia Group B (CALGB) randomized 104 
  previously untreated CLL patients to receive fludarabine at 
a standard dose (25 mg/m2 days 1–5 monthly for 6 cycles) 
with (fludarabine arm) or without concurrent rituximab 
375   mg/ m2 on day 1 (also on day 4 of the first cycle), followed 
by rituximab 375 mg/m2 weekly for 4 weeks starting 8 weeks 
after completion of fludarabine.13 The patients enrolled in the 
fludarabine arm achieved both higher ORR (90% vs 77%) 
and CR rates (47% vs 28%) than those enrolled in the sequen-
tial arm. The median response duration and survival was not 
achieved for either regimen. Although patients with high-risk 
CLL characterized by unmutated IgVH, del(17p) or del(11q) 
undergoing chemoimmunotherapy achieved CR as well as 
patients with good risk CLL, they showed a shorter PFS and 
OS.17 To assess the effect of the addition of rituximab to 
fludarabine therapy Byrd et al retrospectively compared the 
outcome of CLL patients enrolled in two multicenter clinical 
trials in which fludarabine and rituximab (CALGB 9712, 
n = 104) or fludarabine alone (CALGB 9011, n = 178) were 
administered.14 This study showed that patients receiving 
fludarabine and rituximab had a significantly better ORR 
(84% vs 63%), CR (38% vs 20%), as well as a 2-year PFS 
(67% vs 45%) and 2-year OS (93% vs 81%) than patients 
receiving fludarabine alone.14
Similar data have been reported by Schulz et al, who 
treated 31 CLL patients with a combination of fludarabine 
(25 mg/m2 days 1–5 monthly for 6 cycles) and rituximab 
(375 mg/m2 on day 1 of cycles 3–6).18 Similar ORR and CR 
have been observed in previously treated (ORR 91%, CR 
45%) and untreated patients (ORR 85%, CR 25%). Thirty-
two infections have been registered, and 1 patient died of 
cerebral hemorrhage due to thrombocytopenia.18
On the basis of the efficacy of chemoimmunotherapy and 
of the combination of fludarabine and cyclophosphamide54 the 
MDACC group assessed the effectiveness of the FCR sched-
ule (fludarabine 25 mg/m2, cyclophosphamide 250 mg/m2 
days 1–3, and rituximab 375 mg/m2 on day 1 of cycle 1 and 
500 mg/m2 on day 1 of cycles 2–6, monthly for 6 cycles). In 
177 relapsed or refractory CLL patients an ORR of 73% with 
25% of CR was achieved.16 Thirty-two percent of patients 
in CR also showed a complete molecular response.16 In 300 
untreated CLL patients an ORR of 95% with a remarkable 
CR rate of 72% has been reported.15 Six-year OS and fail-
ure-free survival were 77% and 51%, respectively, with a 
median time to progression of 80 months.19 In a multivariate 
analysis of patients receiving fludarabine-based therapy at 
MDACC, the FCR schedule was the strongest independent 
determinant of survival.19 In the trial conducted by the German 
CLL Group in which FCR was compared with FC, patients 
enrolled on the FCR arm showed higher response rates and 
PFS compared to those of the FC arm.20 Although FCR 
caused more neutropenia/leukopenia the incidence of severe 
  infections was not statistically different.20 Recently, statisti-
cally significant differences were observed in OS between the 
two treatment arms. The OS rate at 37.7 months was 84.1% 
in the FCR arm vs 79.0 % in the FC arm (P = 0.01). Notably, 
only patients in Binet stages A and B showed a superior OS 
after FCR treatment (Binet A: HR 0.19, CI 95%, 0.023–1.613, 
P = 0.09; Binet B: HR 0.45, CI 95%, 0.296–0.689, P  0.001; 
Binet C HR1.4, CI 95%, 0.843–2.620, P = 0.168). Notably, 
FCR is the unique first-line combination chemotherapy able 
to improve OS in CLL, corroborating the recommendation 
to use FCR as standard therapy in physically fit patients with 
CLL requiring therapy. Age, sex, FCR-treatment, response, 
number of cycles (0–3), 17p-deletion, increased serum 
levels of thymidine kinase and beta 2-microglobulin and 
unmutated IGVH genes were independent prognostic factors 
predicting OS or PFS.20 The MDACC group also evaluated 
the prognostic relevance of biological markers in patients 
treated with chemoimmunotherapy regimens. Although this 
approach appears to overcome the adverse prognostic impact 
of del(11q),55 it does not seem to modify the poor prognosis 
of cases with unmutated IgVH status.56
Based on the high responses as well as the associated 
toxicities observed in patients treated with FCR, Foon et al 
tested a dose-reduced version of FCR.21 With the intent of 
maintaining efficacy they reduced fludarabine to 20 mg/m2, 
and cyclophosphamide to 150 mg/m2, while rituximab was 
increased to 500 mg/m2 on days 1 and 14 of a 28-day cycle. 
This schedule was followed by rituximab maintenance after 
completion of 6 cycles. In the 48 assessable patients the ORR 
was 100% with a CR rate of 79% (38 patients); 37/38 patients 
in CR achieved a flow-cytometric CR. Median duration of 
CR was 22.3 months and none of the complete responders 
had relapsed at the time of report. Grade 3–4 neutropenia was 
noted in 13% of the cycles of therapy. The authors concluded 
that their regimen (FCR-Lite) maintained the high response 
rate of the FCR regimen, with a lower toxicity.21 With the aim 
of reducing the myelosuppression and immunosuppression 
due to the FCR regimen, La Manna et al recently explored 
the efficacy and safety of a sequential treatment strategy 
with fludarabine 25 mg/m2 on days 1–5 every 4 weeks for 
6 cycles, followed by consolidation with cyclophosphamide 
3000 mg/m2 administered every 3 weeks for 3 cycles, fol-
lowed by consolidation with weekly rituximab 375 mg/m2 75
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for 4 cycles (F  C  R ).23 In the 36 previously untreated 
CLL patients enrolled in the study the ORR was 89% (CR 
61%). Moreover 20 patients (56%) achieved flow cytometric 
CRs, and 12 patients (33%) achieved a molecular CR; 5-year 
survival rate was 71% and 90% patients in molecular CRs 
remain in clinical CR at 5 years. Grade 3 or 4 neutropenia 
occurred in 32 patients (89%), major infectious complications 
occurred in only 5 patients (14%). Although this regimen 
seems to be safe and efficacious, only a randomized study 
could establish whether this schedule is superior in terms of 
response and toxicity to FCR.22
On the light of the good results obtained with the 
  chemotherapy-only regimen of fludarabine, cyclophospha-
mide, and mitoxantrone (FCM), the Spanish group tested 
a new chemoimmunotherapy combination in 72 untreated 
CLL cases: rituximab plus FCM (R-FCM) followed by 
maintenance with rituximab 375 mg/m2 every 3 months for 
2 years for patients who achieved a response.23 The ORR was 
93%, with molecular negative CR and molecular positive CR 
of 46% and 36%, respectively. Thirteen percent of patients 
developed a severe neutropenia and a major infection was 
reported in 8% of cycles. Advanced clinical stage, del(17p), 
or increased serum beta 2-microglobulin levels correlated 
with a lower response rate.23 A similar schedule has been 
tested by the MDACC group in 30 previously untreated 
patients aged 70 years.24 Although similarly good results 
have been reported, they showed that, compared to a histori-
cal group of FCR-treated patients, there were no significant 
differences in term of response and toxicities between the 
two schedules.24
Moreover, rituximab has been combined with other 
purine analogues. La Manna et al have evaluated the 
  efficacy and safety of combination of pentostatin 4 mg/m2, 
cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2 
administered on the same day every 21 days for 6 cycles 
in 46 relapsed/refractory patients (32 CLL and 14 other 
low-grade B-cell neoplasms).25 Supportive measures 
included filgrastim, sulfamethoxazole/trimethoprim, and 
acyclovir. Patients with CLL achieved an ORR of 75% (CR 
rate 25%);  median survival was 44 months. Toxicity was 
acceptable, with grade 3–4 infections in 28%.25 Based on 
these results, 65 previously untreated CLL patients were 
treated with a schedule combining rituximab 375 mg/m2, 
pentostatin 2 mg/m2, and cyclophosphamide 600 mg/m2 
given on day 1, then every 21 days for 6 cycles. Filgrastim 
was administered beginning on day 3.26 Seventy-one per-
cent of patients were IgVH unmutated, 34% CD38 positive 
and 34% ZAP-70 positive. Only 16% of treatment cycles 
had reported a grade 3–4 neutropenia, and 2% a grade 
3–4 infection. ORR was 91% (CR 41%); median PFS was 
33 months.26 Patients with del(17p) showed poor response 
to this schedule. Moreover, although 28% of patients were 
70 years of age, the efficacy and safety of this schedule 
was not significantly affected by age or renal function.27
Knauf et al showed bendamustine superiority over 
  chlorambucil both in terms of OR and PFS in untreated 
CLL patients.57 More recently, bendamustine has been com-
bined with rituximab (BR) in 117 patients with untreated 
CLL.58 Patients received 90 mg/m2 of bendamustine on 
day 1 and 2, combined with 375 mg/m2 and 375 mg/m2 of 
rituximab on day 1 of the first cycle and 500 mg/m2 on day 
1 of subsequent cycles administered every 28 days for up 
to 6 cycles. Grade 3–4 neutropenia and thrombocytopenia 
occurred in 6.5% and 6.1% of all given courses, respec-
tively. Twenty-nine episodes of CTC grade 3 infections 
were documented. The ORR was 90.9% with 32.7% of 
CR.58 Based on these encouraging data the German CLL 
Study Group decided to compare BR to FCR in a phase III 
trial (CLL10 protocol).
Promising results have been reported by Castro et al 
who evaluated rituximab in combination with high-dose 
  methylprednisolone (HDMP) in 28 CLL patients.59 All 
patients received HDMP 1 g/m2 iv days 1–3 of each cycle, 
16/28 patients received 12 doses of rituximab at 375 mg/m2 
weekly over three 4-week cycles, while 12/28 patients 
9 doses of rituximab at 750 mg/m2. The treatment was 
well tolerated and only 4 major infections were registered. 
The ORR was 96% and 9 patients (32%) achieved a CR, 2 
of which were without minimal residual disease (MRD). 
Furthermore no significant difference in CR rates for 
patients 70 years, or those with adverse cytogenetics, 
unmutated IGHV genes or high expression of ZAP-70 or 
CD38 was observed.59
Considering that 1) TNF-α determined infusion toxicity 
when thrice weekly rituximab was administered; 2) TNF- α 
inhibits CLL cell death by upregulating bcl-2 and other anti-
apoptotic proteins; and 3) TNF-α upregulates CD55 and CD59 
antigens,60–64 a combination schedule that combines etaner-
cept, a TNF-α blocking agent, and rituximab was tested in 
relapsed CLL.65 The 36 enrolled patients received etanercept 
25 mg subcutaneously twice weekly (weeks 1–5) and ritux-
imab 375 mg/m2 intravenously thrice weekly (weeks 2–5). Of 
the 34 evaluable patients, 10 (29%) responded, including 9 
PR and 1 CR. No patients with del(17p) achieved a response. 
Median PFS for responsive patients. Grade 3 infections were 
registered in 14% of the patients.6576
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Combination immunotherapy 
with rituximab and alemtuzumab
Since rituximab and alemtuzumab target different antigens 
on the surface of B-cells and the former is effective on nodal 
  disease while alemtuzumab has proven better activity in deplet-
ing CLL cells in the peripheral blood and in the bone marrow,66 
these two monoclonal antibodies have been combined for the 
treatment of CLL patients. In 2003 Faderl et al reported data 
on the safety and efficacy of the combination of rituximab with 
alemtuzumab in 48 patients affected by relapsed/refractory 
lymphoproliferative disorders (32 with CLL, 9 with CLL/pro-
lymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell 
leukemia/lymphoma, and 2 with Richter transformation).67 
The schedule consisted of rituximab at a dose of 375 mg/m2 
weekly for 4 weeks and alemtuzumab given at the loading-
dose schedule of 3 mg, 10 mg and 30 mg on 3 consecutive 
days during the first week of treatment, followed by a dose of 
30 mg on days 3 and 5 of weeks 2–4. Although patients could 
receive a second cycle depending on response and toxicities, 
only 7 (15%) did so. All patients received prophylaxis for 
Pneumocystis carini (Pneumocystis jiroveci) and CMV . ORR 
was 52% among the 32 patients with CLL 63% (2 CLL patients 
achieved a CR); median time to progression was 6 months 
and median OS was 11 months. Most toxicities were grade 
1–2 and infusion-related, and infections occurred in 52% of 
the patients. Only 15% of patients showed a symptomatic 
CMV reactivation and required therapy.67 Zent et al have 
evaluated the combination of rituximab and alemtuzumab as 
early treatment in high-risk CLL patients.68 Thirty untreated 
CLL patients, who had no NCI criteria for treatment and with 
at least 1 marker of high-risk disease [del(17p), del(11q), or a 
  combination of unmutated IgVH and CD38+/ZAP70+] received 
  subcutaneous alemtuzumab with dose escalation (3 mg, 10 mg, 
30 mg) over 3 consecutive days, and then received 30 mg daily 
3 days per week and rituximab at 375 mg/m2 on day 8 and then 
repeated weekly for 4 weeks. All patients received P . carini 
and herpes virus prophylaxis and were monitored for CMV . 
Only 1 patient showed a major infection. CMV reactivation 
occurred in 3 patients (10%) and 1 patient required hospital-
ization for symptomatic CMV infection. ORR was 90% with 
37% of CR. Six patients (29%) achieved a flow cytometric 
remission. Median response duration was 14.4 months. Finally, 
study patients had a significantly longer time from diagnosis to 
first treatment for CLL, according to conventional indications, 
than a comparison cohort with similar biologic risk profiles. 
Nonetheless, although this schedule showed a high efficacy 
in early stage CLL patients with poor prognosis it was not 
curative and most patients progressed.68
Rituximab in combination with 
chemotherapy and immunotherapy
With the aim of improving CR rates and eliminating MRD 
in order to prolong PFS and OS the MDACC group tested 
the activity and safety of the combination of alemtuzumab 
with the FCR regimen.69 Seventy-nine heavily pretreated 
CLL patients received cyclophosphamide 250 mg/m2 on 
days 3–5; fludarabine 25 mg/m2 on days 3–5; alemtuzumab 
30 mg iv on days 1, 3 and 5, and rituximab 375–500 mg/m2 
on day 2 (CFAR), each 28 days for 6 courses. Antibiotic 
  prophylaxis was trimethoprim/sulfamethazole and vala-
cyclovir or valgancyclovir during treatment for 2 months 
after completion. ORR was 65% (CR 24%); median time 
to progression for all responders was 26 months (32 months 
for CR and 18 months for PR pts). Patients with unfavorable 
cytogenetics [del(17p) (16), del(11q) (15), complex (5), and 
del(6q) (1)] achieved 14% CR and 50% PR. Prophylactic 
valgancyclovir was significantly more effective in preventing 
CMV reactivation (3/30 patients, 10%) than prophylactic 
valacyclovir (25/48 patients, 52%). CMV reactivation 
requiring treatment occurred in 12 patients. The incidence 
of major infections (11%) was similar to that observed 
with FCR in the relapsed setting.69 Given these promising 
results, the MDACC group is conducting an ongoing phase 
II study of CFAR as frontline treatment for patients with 
high-risk CLL.70 Since patients 70 years old and with beta 
2-microglobulin 4 when treated with FCR showed a CR rate 
and estimated median PFS significantly lower then similar-
aged patients with beta 2-microglobulin 4, for this subgroup 
of poor prognosis patients the CFAR has been proposed as 
frontline approach.70 In this study of 21 patients evaluable for 
response, ORR was 95% (CR 71%). All responder patients 
but one were free of disease in the bone marrow by flow 
cytometry. There was no significant correlation between 
response rate and quality of response and biological markers 
(IgVH mutation status, FISH status, or ZAP70 or CD38 
expression). Major infections were seen in 2% of courses. 
CMV reactivation occurred in 2/21 patients, both of whom 
received valacyclovir prophylaxis during treatment. In con-
clusion, CFAR is an active and promising frontline regimen 
in higher-risk CLL patients.70 Instead, Byrd et al have 
recently reported data about the efficacy and safety of the 
addition of lumiliximab, an anti-CD23 monoclonal antibody, 
to FCR therapy for the treatment of refractory or relapsed 
CLL patients. Thirty-one patients received either 375 mg/m2 
(n = 3) or 500 mg/m2 (n = 28) of lumiliximab in combination 
with FCR for 6 cycles. ORR was 65% with 52% of CR; 
estimated median PFS for all responders was 28.7 months. 77
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The toxicity profile was similar to that previously reported 
in relapsed CLL patients treated with FCR.71 The addition 
of lumiliximab to FCR therapy was safe and efficacious and 
did not seem to enhance toxicity in previously treated CLL 
patients. A randomized trial comparing lumiliximab plus 
FCR with FCR alone is underway to define the benefit of 
this combination in relapsed patients.
Newer applications
Taking into account that the average age at first diagnosis 
of CLL is about 72 years and patients treated with FCR 
regimen have a high risk of experiencing serious infectious 
complications, this regimen is an appropriate option only 
in a minority of CLL cases. Thus, considering that in the 
elderly population chlorambucil as a single drug is not 
inferior to fludarabine in terms of PFS and OS72,73 and that 
chlorambucil shows low toxicity, low cost and convenience 
as an oral drug, three ongoing trials (one Italian, one German 
and one English) have been testing the safety and efficacy 
of combination of rituximab with chlorambucil as first-line 
therapy for unfit CLL patients.
Since rituximab maintenance therapy provides a 
  significant PFS benefit in patients with indolent B-cell 
NHL74,75 and considering that patients with SLL and CLL 
who had shown at least a stable disease after rituximab 
induction therapy could be successfully retreated at 6-month 
intervals,10 Del Poeta et al tested the efficacy of anti-CD20 
consolidation/maintenance therapy in CLL patients.76 For 
induction treatment, all patients received daily fludarabine 
(25 mg/m2) on days 1–5 at 28-day intervals for a total of 
6 cycles and those with at least a stable disease underwent 
  consolidation/maintenance with 4-monthly cycles of ritux-
imab at a dose of 375 mg/m2 followed by 12-monthly doses 
of rituximab at a dose of 150 mg/m2. All patients experienced 
a long PFS from the end of induction treatment (73% at 
5 years); moreover consolidation and maintenance therapy 
with rituximab prolonged response duration significantly 
in CR or PR cases positive for MRD.76 The efficacy of 
rituximab as post-remissional therapy in CLL patients has 
been also tested by Mauro et al77 In this trial 19 older CLL 
patients ( 60 years) in PR after first-line treatment with 
6 monthly courses of chlorambucil (10 mg/m2/day, days 
1–5) and prednisone (25 mg/m2/day, days 1–5) received   
4-weekly doses of rituximab (375 mg/m2). In 13/19 cases 
(68%) rituximab produced an upgrade of the previous 
response from PR to CR and 2 of the 13 (15%) patients who 
achieved a CR showed a cytometric CR. This study indicates 
that rituximab, given as post-remissional therapy in older 
CLL patients treated with chlorambucil and prednisone 
produced a clinical benefit in the majority of cases.77 Several 
trials designed to evaluate the efficacy of consolidation 
and maintenance of rituximab therapy in CLL patients are 
ongoing.
Furthemore, recently the efficacy of rituximab as pre-
parative regimen for non-myeloablative allogeneic bone 
marrow transplantation (allo-BMT) and as immunomanipu-
lation in combination with donor lymphocyte infusion in 
patients with persistent or progressive CLL after allo-BMT 
has been evaluated.78 This study suggests that this type 
of immunomanipulation after transplant determines an 
increase of PFS. This is probably due to the improvement 
of the graft vs leukemia effect through ADCC and CDC 
stimulated by rituximab,79,80 or to the generation of specific 
cytotoxic T cells induced by anti-CD20 antibody, which 
may promote uptake and cross-presentation of cell-derived 
peptides by antigen-presenting dendritic cells.81
Finally a myriad of monoclonal antibodies with different 
specificities is in preclinical or early clinical investigation. 
Some of these have been designed to target the CD20 
antigen, like rituximab. Ofatumumab, a fully humanized, 
high-affinity monoclonal antibody directed to an epitope on 
CD20 different from the rituximab binding epitope, is most 
advanced in clinical development. Ofatumumab has higher 
affinity for CD20 and activates CDC more effectively than 
rituximab.82,83 A registration study of this monoclonal anti-
body in refractory CLL patients and a phase II study in which 
ofatumumab is administered in combination with fludarabine 
and cyclophosphamide as frontline therapy are ongoing.
Toxicity
The majority of patients (∼80%) treated with rituximab 
have shown at least one adverse event.34 In patients with 
low grade NHL who received rituximab alone the most 
common side effects were infusion-related reactions. These 
adverse effects were usually of mild or moderate severity 
(grade 1–2), of brief duration and observed during the first 
infusion. Grade 1–2 flu-like symptoms such as fever, chills 
and rigors occur in most patients during first infusion, 
although the incidence of infusion-related adverse events 
decreases with subsequent infusions.34 Infusion-related 
adverse effects occur within the first 30 minutes to 2 hours 
of starting the first infusion and usually are reversible with 
interruption or discontinuation of rituximab along with 
supportive care. Approximately 10% of patients showed a 
severe (grade 3–4) infusion-related reaction which may be 
accompanied by bronchospasm, hypotension, angioedema 78
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and/or hypoxia.34 Patients who develop cytokine release 
syndrome associated with tumor lysis syndrome may present 
renal, respiratory or multi-organ failure. Infusion-related 
deaths have been rare (0.04%–0.07% of patients). Patients 
at high-risk of developing severe adverse events are those 
with high lymphocyte counts (25,000 mm3) as well as 
patients with a high tumor burden (eg, bulky disease with 
lesions 10 cm). Severe lymphopenia occurs in about 40% 
of patients, although it does not appear to be associated with 
adverse consequences.34
Interestingly, in the dose-escalation study reported by 
O’Brien et al, rituximab doses of 500 to 1500 mg/m2 were 
associated with minimal adverse events.11 At a dosage level 
of 2250 mg/m2, 8/12 patients showed grade 1 or 2 events, 
but no patients developed severe adverse reactions. Moreover 
1/40 patients with CLL developed grade 3 or 4 adverse 
events compared with 5/10 with other diagnoses (2.5% vs 
50%, P  0.001).11 To minimize the infusion-related toxicity 
Byrd et al administered 100 mg on day 1 and subsequently 
375 mg/m2.12 Thirteen patients (39%) developed transient, 
cytokine-associated infusion toxicity that resolved by the 
third infusion.12 Since tumor lysis syndrome and deaths have 
been reported in patients with high circulating tumor load 
due to the high levels of cytokines released, it is suitable 
for patients with lymphocyte counts 25,000 mm3 where 
in the first treatment cycle the dosage of rituximab is split 
and given on two consecutive days or administering 100 mg 
of rituximab on day 1 the remainder of the dose on day 
2. All patients have to be premedicated with 25 mg of iv 
  diphenhydramine and oral acetaminophen.
Conclusion
In the past decade the most important advances in the 
treatment of CLL patients have been the demonstration of 
improvement in outcome with chemoimmunotherapy. Today, 
for CLL cases with good performance status the treatment 
of choice is the FCR schedule. As initially shown by the 
MDACC group and subsequently confirmed by the German 
CLL group, the FCR schedule enabled a high CR rate to be 
achieved, with MRD being eradicated in a high percentage 
of patients.15,16,20 Moreover these studies highlighted the 
importance of achieving CR and eradicating MRD in CLL, 
since these patients had a longer duration of response than 
patients with residual disease. The German CLL group study 
(CLL8 study) led to the approval of rituximab in combination 
with chemotherapy for CLL in both the US and Europe. Since 
FCR is associated with significant hematologic toxicities, a 
dose-reduced version of FCR (FCR-Lite) and a sequential 
schedule (F  C  R ) have been evaluated.25,26 Although 
these schedules seem to be equally efficacious and safe, only 
randomized trials will ascertain whether these regimens are 
better than FCR in terms of response and toxicity. Since 
patients with elevated serum beta-2 microglobulin achieved 
lower CR rate and shorter PFS when treated with frontline 
chemoimmunotherapy (FCR), for this subgroup of high-risk 
patients a trial to evaluate the safety and efficacy of FCR 
combined with alemtuzumab is ongoing at the MDACC. 
Recently, promising results have been reported with the 
addition of another monoclonal antibody, lumiliximab, to the 
FCR schedule.69 This schedule enabled a high CR rate to be 
achieved, and did not seem to enhance toxicity in previously 
treated patients with CLL.69 Furthermore, promising results 
are expected for the subset of unfit patients from two ongoing 
trials which are evaluating the efficacy and safety of a 
  combination treatment of rituximab with chlorambucil.
A variety of monoclonal antibodies with different 
specificities is in several stages of preclinical or early clinical 
investigation. Some of these have been designed, like ritux-
imab, to target the CD20 surface antigen. Among monoclonal 
antibodies, ofatumumab (anti-CD20) is the most advanced 
in clinical development. A phase III registration study of 
ofatumumab in alkylator-, fludarabine-, and alemtuzumab-
resistant CLL is nearing completion. Thus, monoclonal 
antibody therapy represents a field of highly promising future 
investigation in CLL and will, we hope, lead to a greater 
understanding of how best to use existing antibodies and to 
the introduction of new antibodies.
Acknowledgments/disclosures
Supported in part by Fondazione ‘Amelia Scorza’ onlus, 
Cosenza, Italy. We thank Brigida Gulino for precious sec-
retarial assistance.
The authors disclose no conflicts of interest in relation 
to this work.
References
  1.  Redaelli A, Laskin BL, Stephens JM, et al. The clinical and 
  epidemiological burden of chronic lymphocytic leukaemia. Eur J 
Cancer Care. 2004;13:279–287.
  2.  Catovsky D, Foa R. The Lymphoid Leukaemias. London: Butterworths; 
1990.
  3.  Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and 
outcome of young chronic lymphocytic leukemia patients: a single 
institution study of 204 cases. Blood. 1999;94:448–454.
  4.  Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophos-
phate: a potentially useful agent in chronic lymphocytic leukemia. Nouv 
Rev Fr Hematol. 1988;30:457–459.79
Rituximab in CLL
Cancer Management and Research 2010:2 79
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  5.  Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients 
with chronic lymphocytic leukemia (CLL) receiving fludarabine 
  regimens as initial therapy. Blood. 1998;92:1165–1171.
  6.  Johnson S, Smith AG, Loffler H, et al. Multicentre prospective 
  randomised trial of fludarabine versus cyclophosphamide, doxoru-
bicin and prednisone (CAP) for treatment of advanced-stage chronic 
  lymphocytic leukaemia. The French Cooperative Group on CLL. 
Lancet. 1996;347:1432–1438.
  7.  Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with 
chlorambucil as primary therapy for chronic lymphocytic leukemia. 
N Engl J Med. 2000;343:1750–1757.
  8.  Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of 
fludarabine, CAP, and CHOP in 938 previously untreated stage B and C 
chronic lymphocytic leukemia patients. Blood. 2001;98:2319–2325.
  9.  Huhn D, Von Schilling C, Wilhelm M, et al. Rituximab therapy 
of patients with B-cell chronic lymphocytic leukemia. Blood. 
2001;98:1326–1331.
  10.  Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab 
as first-line and maintenance treatment for patients with chronic 
lymphocytic leukemia or small lymphocytic lymphoma: a phase II 
trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 
2003;21:1746–1751.
  11.  O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-
escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 
2001;19:2165–2170.
  12.  Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly 
dosing schedule in B-cell chronic lymphocytic leukemia and small 
lymphocytic lymphoma demonstrates clinical activity and acceptable 
toxicity. J Clin Oncol. 2001;19:2153–2164.
  13.  Byrd JC, Peterson BL, Morrison VL, et al. Randomized phase 2 study of 
fludarabine with concurrent versus sequential treatment with rituximab 
in symptomatic, untreated patients with chronic lymphocytic leukemia: 
results from Cancer and Leukemia Group B 9712 (CALGB 9712). 
Blood. 2003;119:976–984.
  14.  Byrd JC, Rai K, Peterson BL, et al. The addition of rituximab to 
fludarabine may prolong progression-free survival and overall survival 
in patients with previously untreated chronic lymphocytic leukemia: 
an updated retrospective comparative analysis of CALGB 9712 and 
CALGB 9011. Blood. 2005;105:49–53.
  15.  Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoim-
munotherapy regimen of fludarabine, cyclophosphamide, and rituximab 
as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 
2005;23:4079–4088.
  16.  Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy 
with fludarabine, cyclophosphamide, and rituximab for relapsed 
and refractory chronic lymphocyticleukemia.  J Clin Oncol. 
2005;23:4070–4078.
  17.  Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, 
et al. Select high-risk genetic features predict earlier progression fol-
lowing chemoimmunotherapy with fludarabine and rituximab in chronic 
lymphocytic leukemia: justification for risk-adapted therapy. J Clin 
Oncol. 2006;24:437–443.
  18.  Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, et al. 
Phase 2 study of a combined immunochemotherapy using rituximab 
and fludarabine in patients with chronic lymphocytic leukemia. Blood. 
2002;100:3115–3120.
  19.  Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fluda-
rabine, cyclophosphamide, and rituximab regimen as initial therapy of 
chronic lymphocytic leukemia. Blood 2008;112:975–980.
  20.  Hallek M, Fingerle-Rowson G, Fink AM, et al. First-line treatment 
with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) 
improves overall survival (OS) in previously untreated patients (pts) 
with advanced chronic lymphocytic leukemia (CLL): results of a 
  randomized phase III trial on behalf of an international group of 
investigators and the German CLL Study Group. [abstract] Blood. 
2009;535a.
  21.  Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with 
low-dose fludarabine and cyclophosphamide and high dose rituximab 
in previously untreated patients with chronic lymphocytic leukemia. 
J Clin Oncol. 2009;27:498–503.
  22.  Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, 
high-dose cyclophosphamide, and rituximab in previously untreated 
patients with chronic lymphocytic leukemia produces high-quality 
responses: molecular remissions predict for durable complete responses. 
J Clin Oncol. 2009;27:491–497.
  23.  Bosch F, Abrisqueta P, Villamor N. Rituximab, fludarabine, 
  cyclophosphamide, and mitoxantrone: a new, highly active chemoim-
munotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 
2009;27:4578–4584.
  24.  Faderl S, Wierda W, O’Brien S, Ferrajoli A, Lerner S, Keating MJ. 
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) 
in frontline CLL 70 years. Leuk Res. 2010;34:284–288.
  25.  Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophospha-
mide, and rituximab is an active, well-tolerated regimen for patients 
with previously treated chronic lymphocytic leukemia. J Clin Oncol. 
2006;24:1575–1781.
  26.  Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy 
with pentostatin, cyclophosphamide, and rituximab shows signifi-
cant clinical activity with low accompanying toxicity in previously 
untreated B chronic lymphocytic leukemia. Blood. 2007;109: 
405–411.
  27.  Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, 
and rituximab regimen in older patients with chronic lymphocytic 
leukemia. Cancer. 2007;109:2291–2298.
  28.  Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo 
by a chimeric mouse human monoclonal antibody to CD20. Blood. 
1994;83:435–445.
  29.  Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human 
B cell-associated antigens on leukemias and lymphomas: a model of 
human B cell differentiation. Blood. 1984;63:1424–1433.
  30.  Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen 
identifying lymphoid malignancies of B cell origin. J Clin Invest. 
1981;67:134–140.
  31.  Petryk M, Grossbard ML. Rituximab therapy of B-cell neoplasms. Clin 
Lymphoma. 2000;1:186–194.
  32.  Almasri NM, Duque RE, Iturraspe J, et al. Reduced expression of CD20 
antigen as a characteristic marker for chronic lymphocytic leukemia. 
Am J Hematol. 1992;40:259–263.
  33.  Beum PV , Lindorfer MA, Beurskens F, et al. Complement activation on 
B lymphocytes opsonized with rituximab or ofatumumab produces sub-
stantial changes in membrane structure preceding cell lysis. J Immunol. 
2008;181:822–832.
  34.  Plosker GL, Figgitt DP. Rituximab: a review of its use in non-
Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 
2003;63:803–843.
  35.  Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and 
resistance. Semin Oncol. 2002;29(1 Suppl 2):2–9.
  36.  Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized 
anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor 
FcgammaRIIIa gene. Blood. 2002;99:754–8.
  37.  Carlotti E, Palumbo GA, Oldani E, et al. FcgammaRIIIA and 
  FcgammaRIIA polymorphisms do not predict clinical outcome of 
follicular non-Hodgkin’s lymphoma patients treated with sequential 
CHOP and rituximab. Haematologica. 2007;92:1127–1130.
  38.  Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 
by rituximab results indown-regulation of bcl-2 and sensitization 
of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res. 
2001;7:709–723.
  39.  McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric 
anti-CD20 monoclonal antibody therapy for relapsed indolent 
  lymphoma: half of patients respond to a four-dose treatment program. 
J Clin Oncol. 1998;16:2825–2833.80
Gentile et al
Cancer Management and Research 2010:2 80
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  40.  Daydé D, Ternant D, Ohresser M, et al. Tumor burden influences 
  exposure and response to rituximab: pharmacokinetic-pharmacodynamic 
modeling using a syngeneic bioluminescent murine model expressing 
human CD20. Blood. 2009;113:3765–3772.
  41.  Fust G, Czink E, Minh D, et al. Depressed classical complement path-
way activities in chronic lymphocytic leukemia. Clin Exp Immunol. 
1985;60:489–495.
  42.  Klepfish A, Gilles L, Ioannis K, Eliezer R, Ami S. Enhancing the 
action of rituximab in chronic lymphocytic leukemia by adding fresh 
frozen plasma: complement/rituximab interactions and clinical results 
in refractory CLL. Ann N Y Acad Sci. 2009;1173:865–873.
  43.  Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial 
using escalating single-dose infusion of chimeric anti-CD20 monoclonal 
antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. 
Blood. 1994;84:2457–2466.
  44.  Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDECC2B8: results 
of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s 
lymphoma. J Clin Oncol. 1997;15:3266–3274.
  45.  Maloney DG, Grillo-Lopez AJ, White CA, et al. IDECC2B8 (Rituximab) 
anti-CD20 monoclonal antibody therapy in patients with relapsed low-
grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195.
  46.  Grillo-Lopez AJ. Rituximab: an insider’s historical perspective. Semin 
Oncol. 2000;27:9–16.
  47.  McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG. Clinical 
status and optimal use of rituximab for B-cell lymphomas. Oncology 
(Williston Park). 1998;12:1763–1769.
  48.  Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-
C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade 
non-Hodgkin’s lymphoma and lymphoproliferative disorders: evalua-
tion of response on 48 patients. Eur J Haematol. 1999;62:76–82.
  49.  Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. 
Cytokine-release syndrome in patients with B-cell chronic lympho-
cytic leukemia and high lymphocyte counts after treatment with an 
anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 
1999;94:2217–2224.
  50.  Ladetto M, Bergui L, Ricca I, Campana S, Pileri A, Tarella C. Ritux-
imab anti-CD20 monoclonal antibody induces marked but transient 
reductions of peripheral blood lymphocytes in chronic lymphocytic 
leukaemia patients. Med Oncol. 2000;17:203–210.
  51.  Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody 
rituximab has efficacy in chronic lymphocytic leukaemia: results from 
a Nordic multicentre study. Eur J Haematol. 2002;69:129–134.
  52.  Thomas D, O’Brien S, Giles FJ, et al. Single agent rituxan in early 
stage chronic lymphocytic leukemia (CLL). [abstract] Blood. 
2001;98:364a.
  53.  Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH, et al. 
Interphase cytogenetic abnormalities in chronic lymphocytic leukemia 
may predict response to rituximab. Cancer Res. 2003;63:36–38.
  54.  O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine 
and cyclophosphamide combination regimen in chronic lymphocytic 
leukemia. J Clin Oncol. 2001;19:1414–1420.
  55.  Tsimberidou AM, Tam C, Abruzzo LV , et al. Chemoimmunotherapy 
may overcome the adverse prognostic significance of 11q deletion 
in previously untreated patients with chronic lymphocytic leukemia. 
Cancer. 2009;115:373–80.
  56.  Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin 
VH somatic mutation status in patients with chronic lymphocytic leuke-
mia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or 
related chemoimmunotherapy regimens. Blood 2009;113:3168–71.
  57.  Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study 
of bendamustine compared with chlorambucil in previously untreated 
patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;10; 
27:4378–84.
  58.  Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined 
with rituximab (BR) in first-line therapy of advanced CLL: a multicenter 
phase II trial of the German CLL Study Group (GCLLSG). [abstract] 
Blood. 2009;114:205a.
  59.  Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, 
Kipps TJ. Rituximab in combination with high-dose methylpredniso-
lone for the treatment of chronic lymphocytic leukemia. Leukemia. 
2009;23:1779–1789.
  60.  Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-
20-induced apoptosis of malignant human B cells. Cancer Immunol 
Immunother. 2000;48:673–683.
  61.  Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced 
apoptosis: src-family kinase, the proximal regulator of tyrosine phos-
phorylation, calcium influx, and caspase 3-dependent apoptosis. Blood 
Cells Mol Dis. 2000;26:133–143.
  62.  Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, 
et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal 
antibody rituximab in vitro: CD55 and CD59 regulate complement-
mediated cell lysis. Blood. 2000;95:3900–3908.
  63.  Tangye SG, Raison RL. Human cytokines suppress apoptosis of leu-
kaemic CD5+ B cells and preserve expression of bcl-2. Immunol Cell 
Biol. 1997;75: 127–135.
  64.  Adami F, Guarini A, Pini M, Siviero F, Sancetta R, Massaia M,   
et al. Serum levels of tumour necrosis factor-alpha in patients with 
B-cell chronic lymphocytic leukaemia. Eur J Cancer. 1994;30A: 
1259–1263.
  65.  Woyach JA, Lin TS, Lucas MS, et al. A phase I/II study of rituximab 
and etanercept in patients with chronic lymphocytic leukemia and small 
lymphocytic lymphoma. Leukemia. 2009;23:912–918.
  66.  Lundin J,Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal 
antibody in therapy for previously treated low-grade non-Hodgkin’s 
lymphomas: a phase II multicenter study. J Clin Oncol. 1998;16: 
3257–3263.
  67.  Faderl S, Thomas DA, O’Brien S, et al. Experience with alemtuzumab 
plus rituximab in patients with relapsed and refractory lymphoid malig-
nancies. Blood. 2003;101:3413–3415.
  68.  Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk 
chronic lymphocytic leukemia with alemtuzumab and rituximab. 
Cancer. 2008;113:2110–2118.
  69.  Wierda WG, O’Brien S, Faderl S, Ferrajoli A, Ravandi-Kashani F, 
Cortes J, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, 
and rituximab (CFAR), an active regimen for heavily treated patients 
with CLL. [abstract] Blood. 2006;108:14a.
  70.  Wierda WG, O’Brien S, Ferrajoli A, et al. Combined Cyclophospha-
mide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active 
Frontline Regimen for High-Risk Patients with CLL. [abstract] Blood. 
2007;110:628a.
  71.  Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab 
combined with fludarabine, cyclophosphamide, and rituximab in 
patients with relapsed or refractory chronic lymphocytic leukemia. 
Blood. 2010;115:489–495.
  72.  Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine 
plus cyclophosphamide for patients with chronic lymphocytic leu-
kaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 
2007;370:230–239.
  73.  Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with 
fludarabine compared with chlorambucil does not result in a major ben-
efit for elderly patients with advanced chronic lymphocytic leukemia. 
Blood. 2009;114:3382–3391.
  74.  Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with 
rituximab in patients with follicular lymphoma significantly increases 
event-free survival and response duration compared with the standard 
weekly x 4 schedule. Blood. 2004;103:4416–4423.
  75.  Hainsworth JD, Lichty S, Shaffer DW, et al. Maximizing therapeutic 
benefit of rituximab maintenance therapy versus re-treatment at progres-
sion in patients with indolent non-Hodgkin’s lymphoma – a randomized 
phase II trial of the Minnie Pearl Cancer Research Network. J Clin 
Oncol. 2005;23:1088–1095.
  76.  Del Poeta G, Del Principe MI, Ragusa D, et al. Rituximab maintenance 
following chemoimmunotherapy improves outcome in B-cell chronic 
lymphocytic leukemia. [abstract] Blood. 2009;114:2364a.Cancer Management and Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/cancer-management-and-research-journal
Cancer Management and Research is an international, peer-reviewed 
open access journal focusing on cancer research and the optimal use of 
preventative and integrated treatment interventions to achieve improved 
outcomes, enhanced survival and quality of life for the cancer patient. 
The journal welcomes original research, clinical & epidemiological 
studies, reviews & evaluations, guidelines, expert opinion & commen-
tary, case reports & extended reports. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/ 




Cancer Management and Research 2010:2 81
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  81.  Hsu FJ, Komarovskaya M. CTLA4 blockade maximizes antitumor 
T-cell activation by dendritic cells presenting idiotype protein or 
opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother. 
2002;25:455–468.
  82.  Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of 
human CD20 monoclonal antibodies is linked to unique epitopes on 
CD20. J Immunol. 2006;177:362–371.
  83.  Teeling JL, French RR, Cragg MS, et al. Characterization of new human 
CD20 monoclonal antibodies with potent cytolytic activity against 
non-Hodgkin lymphomas. Blood. 2004;104:1793–1800.
  77.  Mauro FR, Del Giudice I, Gentile M, et al. Post-remissional rituximab 
administration for the treatment of older chronic lymphocytic leucemia 
(CLL) patients responsive to first-line therapy with chlorambucil and 
prednisone. [abstract] Haematologica. 2007;44:124a.
  78.  Khouri IF, Saliba RM, Admirand J, et al. Graft-versus leukaemia effect 
after non-myeloablative haematopoietic transplantation can overcome 
the unfavourable expression of ZAP-70 in refractory chronic lympho-
cytic leukaemia. Br J Haematol. 2007;137:355–363.
  79.  Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc 
receptors modulate in vivo toxicity against tumor targets. Nat Med. 
2000;6:443–446.
  80.  Pfeiffer M, Stanojevic S, Feuchtinger T, Greil J, et al. Rituximab 
  mediates in vitro antileukemic activity in pediatric patients after allo-
geneic transplantation. Bone Marrow Transplant. 2005;36:91–97.